Seroquel XR in Schizophrenia Relapse Prevention
Completed
- Conditions
- Schizophrenia Relapse Prevention
- Registration Number
- NCT00990626
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1600
Inclusion Criteria
- Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month
Exclusion Criteria
- Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of patients remained relapse free after 6 months of treatment
- Secondary Outcome Measures
Name Time Method Adherence rate of patients Quality of Life (QoL )
Trial Locations
- Locations (1)
Research Site
🇭🇺Veszprem, Hungary